Liminatus Pharma Amends Proposed $320M Merger Deal With InnocsAI As Closing Now Anticipated Before Shareholder Approval On July 2
Liminatus Pharma, Inc. (Nasdaq: LIMN ) ("Liminatus" or the "Company"), a biotechnology company developing innovative cancer therapies, today announced that it has amended and restated the previously announced definitive merger agreement with InnocsAI LLC ("InnocsAI"), an oncology biotechnology company focused on next-g